Abstract OT1-04-04: A phase 2 randomized, double-blind, placebo-controlled trial of endocrine therapy ± radium-223 dichloride in HER2-negative, hormone receptor–positive breast cancer patients with bone metastases
RE Coleman(Weston Park Cancer Centre), HS Rugo(Texas Oncology), Georgeta Fried(Roche (Switzerland)), Ruochang Li(Bayer (United States)), AG Sawhney(Bayer (United States)), Oana Petrenciuc(Bayer (United States))
Cited by 2
Related Papers
Olaparib Monotherapy in Patients With Advanced Cancer and a Germline <i>BRCA1/2</i> Mutation
|Journal of Clinical Oncology|2014|1.7k
Survival and safety of exemestane versus tamoxifen after 2–3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial
|The Lancet|2007|912
Efficacy and safety of olaparib monotherapy in germline BRCA1 / 2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy
|Gynecologic Oncology|2015|301
Clinical outcomes in ER+ HER2 -node-positive breast cancer patients who were treated according to the Recurrence Score results: evidence from a large prospectively designed registry
|npj Breast Cancer|2017|87
Comparing Relaxation Training and Cognitive-Behavioral Group Therapy for Women With Breast Cancer
|Research on Social Work Practice|2007|82